Aerie Pharmaceuticals, a RTP based biotech firm, recently announced the close of a $30M series B round of funding. As a discovery and development firm in the field of ophthalmology, this round will help Aerie further develop their portfolio of treatments for glaucoma. Aerie raised a total of $61M since inception.
Aerie joined the CED community in 2005. Tom van Haarlem, CEO of Aerie, spoke at CED’s Biotech Conference in February.
Read the full press release here